Provided by Tiger Trade Technology Pte. Ltd.

Celcuity Inc

80.61
-4.3000-5.06%
Post-market: 81.000.3900+0.48%17:51 EDT
Volume:1.41M
Turnover:113.93M
Market Cap:3.93B
PE:-18.65
High:85.17
Open:84.89
Low:79.77
Close:84.91
52wk High:151.02
52wk Low:44.42
Shares:48.77M
Float Shares:29.72M
Volume Ratio:1.47
T/O Rate:4.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3223
EPS(LYR):-3.7900
ROE:-1433.70%
ROA:-25.78%
PB:-307.57
PE(LYR):-21.27

Loading ...

Celcuity amends 8-K to provide full text of amended Item 5.02 disclosures

Reuters
·
May 20

Celcuity shareholders approve 2026 stock incentive plan at annual meeting

Reuters
·
May 19

Celcuity Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 18

U.S. RESEARCH ROUNDUP-Exxon Mobil, Northrop Grumman, Regeneron Pharmaceuticals

Reuters
·
May 18

Celcuity Price Target Maintained With a $157.00/Share by Needham

Dow Jones
·
May 15

Guggenheim Reaffirms Their Buy Rating on Celcuity (CELC)

TIPRANKS
·
May 15

Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF)

TIPRANKS
·
May 15

Celcuity Q1 FY26 net loss widens 43% to $52.84 million

Reuters
·
May 15

Celcuity Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 15

Notable companies reporting after market close

TIPRANKS
·
May 15

Biotech firm Celcuity reports smaller-than-expected Q1 loss

Reuters
·
May 15

Celcuity Q1 Adjusted Loss Widens

MT Newswires Live
·
May 15

Celcuity Q1 Adj. EPS $(0.86) Beats $(1.05) Estimate

Benzinga Earnings
·
May 15

BRIEF-Celcuity Q1 Adjusted EPS USD -0.86 Vs. IBES Estimate USD -1.05

Reuters
·
May 15

Celcuity Q1 EPS USD -0.97

THOMSON REUTERS
·
May 15

Celcuity Inc: Expect Cash, Cash Equivalents, Investments & Drawdowns on Debt Facility to Finance Operations Through 2027

THOMSON REUTERS
·
May 15

Analysts Are Bullish on Top Healthcare Stocks: Celcuity (CELC), Rubicon Organics (ROMJF)

TIPRANKS
·
May 15

Celcuity announces amendments to VIKTORIA-2 clinical trial of gedatolisib

TIPRANKS
·
May 14

Stock Track | Celcuity Soars 5.04% Intraday on FDA Priority Review and Expanded Phase 3 Trial for Breast Cancer Drug

Stock Track
·
May 14

Celcuity Expands Gedatolisib Phase 3 Program in First-Line Breast Cancer Setting

MT Newswires Live
·
May 14